Physician profile
Samuel Deel
NPI 1568625127
$4,892.84
in general payments reported to CMS, 2019-2025
37 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $841 · 2021: $758 · 2022: $1,039 · 2023: $816 · 2024: $463 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $829.27 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $430.61 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $339.02 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Supernus Pharmaceuticals, INC. | $305.36 | 2020-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $286.48 | 2019-2024 | Trintellix, Aralast |
| Amarin Pharma, INC. | $260.49 | 2019-2021 | |
| Abbvie INC. | $260.24 | 2021-2025 | Ubrelvy, Vraylar |
| Corium, LLC | $256.63 | 2022-2024 | Azstarys |
| Lundbeck LLC | $208.43 | 2020-2025 | Vyepti |
| Janssen Pharmaceuticals, INC | $187.28 | 2019-2022 | |
| Exact Sciences Corporation | $145.28 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $132.14 | 2019-2023 | |
| Lilly USA, LLC | $126.73 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.28 | 2022-2024 | |
| Glaxosmithkline, LLC. | $94.31 | 2021-2025 | Shingrix, Arexvy |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Deel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.